Psoriasis and inflammatory bowel disease: links and risks

References

• NestleFOKaplanDHBarkerJPsoriasisN Engl J Med2009361549650919641206
   PubMed Web of Science ®Google Scholar
• BaumgartDCSandbornWJInflammatory bowel disease: clinical aspects and established and evolving therapiesLancet20073691641165717499606
   PubMed Web of Science ®Google Scholar
• LolliESaracenoRCalabreseEPsoriasis phenotype in inflammatory bowel disease: a case-control prospective studyJ Crohns Colitis20159969970725908719
   PubMed Web of Science ®Google Scholar
• ZippiMCorradoCPicaRExtraintestinal manifestations in a large series of Italian inflammatory bowel disease patientsWorld J Gastroenterol20142046174631746725516659
   PubMed Web of Science ®Google Scholar
• MolodeckyNASoonISRabiDMIncreasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic reviewGastroenterology2012142465422001864
   PubMed Web of Science ®Google Scholar
• LoftusEVJrClinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influencesGastroenterology200412661504151715168363
   PubMed Web of Science ®Google Scholar
• ParisiRSymmonsDPGriffithsCEGlobal epidemiology of psoriasis: a systematic review of incidence and prevalenceJ Invest Dermatol2013133237738523014338
   PubMed Web of Science ®Google Scholar
• YangHPlevySETaylorKLinkage of Crohn’s disease to the major histocompatibility complex region is detected by multiple non-parametric analysesGut199944451952610075959
   PubMed Web of Science ®Google Scholar
• OestreicherJWaltersIKikuchiTMolecular classification of psoriasis disease-associated genes through pharmacogenomic expression profilingPharmacogenomics J20011427228711911124
   PubMedGoogle Scholar
• FarberEMNallMLWatsonWNatural history of psoriasis in 61 twin pairsArch Dermatol197410922072114814926
   PubMedGoogle Scholar
• WattsDASatsangiJThe genetic jigsaw of inflammatory bowel diseaseGut200250Suppl 3III31III3611953330
   PubMedGoogle Scholar
• LeeFIBellarySVFrancisCIncreased occurrence of psoriasis in patients with Crohn’s disease and their relativesAm J Gastroenterol19908589629632375323
   PubMed Web of Science ®Google Scholar
• BernsteinCNWajdaABlanchardJFThe clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based studyGastroenterology2005129382783616143122
   PubMed Web of Science ®Google Scholar
• CohenADDreiherJBirkenfeldSPsoriasis associated with ulcerative colitis and Crohn’s diseaseJ Eur Acad Dermatol Venereol200923556156519207663
   PubMed Web of Science ®Google Scholar
• ChandraARayASenapatiSChatterjeeRGenetic and epigenetic basis of psoriasis pathogenesisMol Immunol201564231332325594889
   PubMed Web of Science ®Google Scholar
• ImielinskiMBaldassanoRNGriffithsACommon variants at five new loci associated with early-onset inflammatory bowel diseaseNat Genet200941121335134019915574
   PubMed Web of Science ®Google Scholar
• SkrozaNProiettiIPampenaRCorrelations between psoriasis and inflammatory bowel diseasesBiomed Res Int2013201398390223971052
   PubMed Web of Science ®Google Scholar
• EllinghausDEllinghausENairRPCombined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility lociAm J Hum Genet201290463664722482804
   PubMed Web of Science ®Google Scholar
• DzutsevAGoldszmidRSViaudSZitvogelLTrinchieriGThe role of the microbiota in inflammation, carcinogenesis, and cancer therapyEur J Immunol2015451173125328099
   PubMed Web of Science ®Google Scholar
• SekirovIRussellLAntunesCFinlayBGut microbiota in health and diseasePhysiol Rev201090385990420664075
   PubMed Web of Science ®Google Scholar
• CaponeKADowdSEStamatasGNNikolovskiJDiversity of the human skin microbiome early in lifeJ Invest Dermatol2011131102026203221697884
   PubMed Web of Science ®Google Scholar
• BassoPJFonsecaMTBonfaGAssociation among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel diseaseBraz J Med Biol Res201447972773725075576
   PubMed Web of Science ®Google Scholar
• FurusawaYObataYFukudaSCommensal microbe-derived butyrate induces the differentiation of colonic regulatory T cellsNature201350444645024226770
   PubMed Web of Science ®Google Scholar
• QiuJGuoXChenZMGroup 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microfloraImmunity20133938639923954130
   PubMed Web of Science ®Google Scholar
• OttSJMusfeldtMTimmisKNHampeJWenderothDFSchreiberSIn vitro alterations of intestinal bacterial microbiota in fecal samples during storageDiagn Microbiol Infect Dis200450423724515582296
   PubMed Web of Science ®Google Scholar
• WalkerAWSandersonJDChurcherCHigh-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel diseaseBMC Microbiol201111721219646
   PubMed Web of Science ®Google Scholar
• WillingBHalfvarsonJDicksvedJTwin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn’s diseaseInflamm Bowel Dis20091565366019023901
   PubMed Web of Science ®Google Scholar
• FrankDNRobertsonCEHammCMDisease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseasesInflamm Bowel Dis20111717918420839241
   PubMed Web of Science ®Google Scholar
• WehkampJSalzmanNHPorterEReduced Paneth cell α-defensins in ileal Crohn’s diseaseProc Natl Acad Sci U S A2005102181291813416330776
   PubMed Web of Science ®Google Scholar
• RauschPRehmanAKünzelSColonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotypeProc Natl Acad Sci U S A201110847190301903522068912
   PubMed Web of Science ®Google Scholar
• TamboliCPNeutCDesreumauxPColompelJFDysbiosis as a prerequisite for IBDGut20045371057
   Web of Science ®Google Scholar
• RookGARaisonCLLowryCAHaleLPLochsHMicrobiota, immunoregulatory old friends and psychiatric disordersAdv Exp Med Biol201481731935624997041
   PubMed Web of Science ®Google Scholar
• SwidsinskiAWeberJLoening-BauckeVHaleLPLochsHSpatial organization and composition of the mucosal florain patients with inflammatory bowel diseaseJ Clin Microbiol20054373380338916000463
   PubMed Web of Science ®Google Scholar
• OkaAMabuchiTOzawaAInokoHCurrent understanding of human genetics and genetic analysis of psoriasisJ Dermatol201239323124122352847
   PubMed Web of Science ®Google Scholar
• GalloRLNakatsujiTMicrobial symbiosis with the innate immune defense system of the skinJ Invest Dermatol2011131101974198021697881
   PubMed Web of Science ®Google Scholar
• GaoZTsengCHStroberBEPeiZBlaserMJSubstantial alterations of the cutaneous bacterial biota in psoriatic lesionsPLoS One200837e271918648509
   PubMed Web of Science ®Google Scholar
• AlekseyenkoAVPerez-PerezGIDe SouzaACommunity differentiation of the cutaneous microbiota in psoriasisMicrobiome2013113124451201
   PubMed Web of Science ®Google Scholar
• FryLBakerBSPowlesAVFahlenAEngstrandLIs chronic plaque psoriasis triggered by microbiota in the skin?Br J Dermatol20131691475223521130
   PubMed Web of Science ®Google Scholar
• BassukasIDGaitanisGHundeikerMLeprosy and the natural selection for psoriasisMed Hypotheses201278118319022079652
   PubMed Web of Science ®Google Scholar
• McFaddenJPBakerBSPowlesAVFryLPsoriasis and streptococci: the natural selection of psoriasis revisitedBr J Dermatol2009160592993719309365
   PubMed Web of Science ®Google Scholar
• MakRKHundhausenCNestleFOProgress in understanding the immunopathogenesis of psoriasisActas Dermosifiliogr2009100Suppl 221320096156
   PubMedGoogle Scholar
• MorizaneSGalloRLAntimicrobial peptides in the pathogenesis of psoriasisJ Dermatol201239322
   Web of Science ®Google Scholar
• SweeneyCMTobinAMKirbyBInnate immunity in the pathogenesis of psoriasisArch Dermatol Res20113031069170521863252
   PubMed Web of Science ®Google Scholar
• Di MeglioPDuarteJHAhlforsHActivation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditionsImmunity2014406989100124909886
   PubMed Web of Science ®Google Scholar
• MagiatisPPappasPGaitanisGMalassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skinJ Invest Dermatol201313382023203023448877
   PubMed Web of Science ®Google Scholar
• LinYKLeuYLYangSHChenHWWangCTPangJHAnti-psoriatic effects of indigo naturalis on the proliferation and differentiation of keratinocytes within dirubin as the active componentJ Dermatol Sci200954316817419303259
   PubMed Web of Science ®Google Scholar
• SalzmanNHMicrobiota-immune system interaction: an uneasy allianceCurr Opin Microbiol20111419910520971034
   PubMed Web of Science ®Google Scholar
• GerovaVAStoynovSGKatsarovDSSvinarovDAIncreased intestinal permeability in inflammatory bowel diseases assessed by iohexol testWorld J Gastroenterol201117172211221521633531
   PubMed Web of Science ®Google Scholar
• KiesslichRDuckworthCAMoussataDLocal barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel diseaseGut20126181146115322115910
   PubMed Web of Science ®Google Scholar
• MankertzJTavalaliSSchmitzHExpression from the human occludin promoter is affected by tumor necrosis factor α and interferon gammaJ Cell Sci2000113Pt 112085209010806119
   PubMed Web of Science ®Google Scholar
• BuisineMPDesreumauxPLeteurtreEMucin gene expression in intestinal epithelial cells in Crohn’s diseaseGut200149454455111559653
   PubMed Web of Science ®Google Scholar
• CarioEPodolskyDKDifferential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel diseaseInfect Immun200068127010701711083826
   PubMed Web of Science ®Google Scholar
• HausmannMKiesslingSMestermannSToll-like receptors 2 and 4 are up-regulated during intestinal inflammationGastroenterology200212271987200012055604
   PubMed Web of Science ®Google Scholar
• ViscontiBPaolinoGCarottiSImmunohistochemical expression of VDR is associated with reduced integrity of tight junction complex in psoriatic skinJ Eur Acad Dermatol Venereol201529102038204225220655
   PubMed Web of Science ®Google Scholar
• RobersonEDBowcockAMPsoriasis genetics: breaking the barrierTrends Genet201026941542320692714
   PubMed Web of Science ®Google Scholar
• PanzerRBlobelCFölster-HolstRProkschETLR2 and TLR4 expression in atopic dermatitis, contact dermatitis and psoriasisExp Dermatol201423536436624661005
   PubMed Web of Science ®Google Scholar
• NiessJHBrandSGuXCX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearanceScience200530725425815653504
   PubMed Web of Science ®Google Scholar
• VarolCZigmondEJungSSecuring the immune tightrope: mononuclear phagocytes in the intestinal lamina propriaNat Rev Immunol201010641542620498668
   PubMed Web of Science ®Google Scholar
• BaumgartDCThomasSPrzesdzingIExaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel diseaseClin Exp Immunol2009157342343619664152
   PubMed Web of Science ®Google Scholar
• AnnackerOCoombesJLMalmstromVEssential role for CD103 in the T cell-mediated regulation of experimental colitisJ Exp Med200520281051106116216886
   PubMed Web of Science ®Google Scholar
• SiddiquiKRLaffontSPowrieFE-cadherin marks a subset of inflammatory dendritic cells that promote T cell-mediated colitisImmunity201032455756720399121
   PubMed Web of Science ®Google Scholar
• LealMCDäbritzJImmunoregulatory role of myeloid-derived cells in inflammatory bowel diseaseInflamm Bowel Dis201521122936294726244650
   PubMed Web of Science ®Google Scholar
• GlitznerEKorosecABrunnerPMSpecific roles for dendritic cell subsets during initiation and progression of psoriasisEMBO Mol Med20146101312132725216727
   PubMed Web of Science ®Google Scholar
• GordonKBBonishBKPatelTLeonardiCLNickoloffBJThe tumour necrosis factor-α inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaquesBr J Dermatol2005153594595316225604
   PubMed Web of Science ®Google Scholar
• NestleFOConradCTun-KyiAPlasmacytoid predendritic cells initiate psoriasis through interferon-α productionJ Exp Med2005202113514315998792
   PubMed Web of Science ®Google Scholar
• AlbanesiCScarponiCPallottaSChemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitmentJ Exp Med2009206124925819114666
   PubMed Web of Science ®Google Scholar
• CerioRGriffithsCECooperKDNickoloffBJHeadingtonJTCharacterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skinBr J Dermatol198912144214312576222
   PubMed Web of Science ®Google Scholar
• WillenborgSEmingSAMacrophages – sensors and effectors coordinating skin damage and repairJ Dtsch Dermatol Ges201412321422324580874
   PubMed Web of Science ®Google Scholar
• MantovaniAAllavenaPSicaATumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progressionEur J Cancer200440111660166715251154
   PubMed Web of Science ®Google Scholar
• BainCCScottCLUronen-HanssonHResident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursorsMucosal Immunol2013649851022990622
   PubMed Web of Science ®Google Scholar
• SchenkMBouchonASeiboldFMuellerCTREM-1 – expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseasesJ Clin Invest2007117103097310617853946
   PubMed Web of Science ®Google Scholar
• NickoloffBJBonishBKMarbleDJLessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammationJ Investig Dermatol Symp Proc20061111629
   PubMed Web of Science ®Google Scholar
• KarinMLawrenceTNizetVInnate immunity gone awry: linking microbial infections to chronic inflammation and cancerCell200612482383516497591
   PubMed Web of Science ®Google Scholar
• ThepenTvan VuurenAJKiekensRCDamenCAVooijsWCvan De WinkelJGResolution of cutaneous inflammation after local elimination of macrophagesNat Biotechnol2000181485110625390
   PubMed Web of Science ®Google Scholar
• GilroyDWNewsonJSawmynadenPWilloughbyDACroxtallJDA novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammationFASEB J200418348949815003994
   PubMed Web of Science ®Google Scholar
• LinHHFaunceDEStaceyMThe macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral toleranceJ Exp Med2005201101615162515883173
   PubMed Web of Science ®Google Scholar
• KritasSKSagginiAVarvaraGImpact of mast cells on the skinInt J Immunopathol Pharmacol201326485585924355220
   PubMed Web of Science ®Google Scholar
• HamiltonMJFreiSMStevensRLThe multifaceted mast cell in inflammatory bowel diseaseInflamm Bowel Dis201420122364237825401721
   PubMed Web of Science ®Google Scholar
• NishidaYMuraseKIsomotoHDifferent distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel diseaseHepatogastroenterology20024967868212063968
   PubMedGoogle Scholar
• NolteHSpjeldnaesNKruseAWindelborgBHistamine release from gut mast cells from patients with inflammatory bowel diseasesGut19903177917941695160
   PubMed Web of Science ®Google Scholar
• BischoffSCWedemeyerJHerrmannAQuantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel diseaseHistopathology19962811138838115
   PubMed Web of Science ®Google Scholar
• FoxCCLazenbyAJMooreWCYardleyJHBaylessTMLichtensteinLMEnhancement of human intestinal mast cell mediator release in active ulcerative colitisGastroenterology1990991191241693122
   PubMed Web of Science ®Google Scholar
• GroschwitzKRAhrensROsterfeldHMast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanismProc Natl Acad Sci U S A200910652223812238620018751
   PubMed Web of Science ®Google Scholar
• WoutersMMVicarioMSantosJThe role of mast cells in functional GI disordersGut201665115516826194403
   PubMed Web of Science ®Google Scholar
• HarvimaITNilssonGSuttleMMNaukkarinenAIs there a role for mast cells in psoriasis?Arch Dermatol Res2008300946147818719932
   PubMed Web of Science ®Google Scholar
• CoxAJMast cells in psoriasisCoxAJFarberEMPsoriasis, Proceedings of the Second International Symposium, Stanford UniversityNew York, NYYorke Medical Books19773643
   Google Scholar
• ArckPCSlominskiATheoharidesTCPetersEMPausRNeuroimmunology of stress: skin takes center stageJ Invest Dermatol200612681697170416845409
   PubMed Web of Science ®Google Scholar
• RijnierseANijkampFPKraneveldADMast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndromePharmacol Ther2007116220723517719089
   PubMed Web of Science ®Google Scholar
• TheoharidesTCThe mast cell: a neuroimmunoendocrine master playerInt J Tissue React19961811218880375
   PubMedGoogle Scholar
• DunphySGardinerCMNK cells and psoriasisJ Biomed Biotechnol2011201124831721687543
   PubMedGoogle Scholar
• YadavPKChenCLiuZPotential role of NK cells in the pathogenesis of inflammatory bowel diseaseJ Biomed Biotechnol2011201134853021687547
   PubMedGoogle Scholar
• LiuZYangLCuiYIL-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel diseaseInflamm Bowel Dis20091581133114419322899
   PubMed Web of Science ®Google Scholar
• TakayamaTKamadaNChinenHImbalance of NKp44(+) NKp46(−) and NKp44(NKp46+) natural killer cells in the intestinal mucosa of patients with Crohn’s diseaseGastroenterology20101393882892892.e1320638936
   PubMed Web of Science ®Google Scholar
• OttavianiCNasorriFBediniCde PitàOGirolomoniGCavaniACD56 bright CD16(−) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammationEur J Immunol200636111812816323244
   PubMed Web of Science ®Google Scholar
• YawalkarNSchmidSBraathenLRPichlerWJPerforin and granzyme B may contribute to skin inflammation in atopic dermatitis and psoriasisBr J Dermatol200114461133113911422032
   PubMed Web of Science ®Google Scholar
• GiacomelliRPassacantandoAFrieriGCirculating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patientsClin Exp Immunol1999115172779933422
   PubMed Web of Science ®Google Scholar
• SonnenbergGFMjösbergJSpitsHArtisDSnapShot: innate lymphoid cellsImmunity2013393622622.e124012419
   PubMedGoogle Scholar
• CupedoTCrellinNKPapazianNHuman fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cellsNat Immunol2009101667419029905
   PubMed Web of Science ®Google Scholar
• BuonocoreSAhernPPUhligHHInnate lymphoid cells drive interleukin-23-dependent innate intestinal pathologyNature201046472931371137520393462
   PubMed Web of Science ®Google Scholar
• LeeJSCellaMMcDonaldKGAHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of NotchNat Immunol201213144151
   Web of Science ®Google Scholar
• LongmanRSDiehlGEVictorioDACX3CR1+ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22J Exp Med201421181571158325024136
   PubMed Web of Science ®Google Scholar
• HanashAMDudakovJAHuaGInterleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host diseaseImmunity201224339350
   Web of Science ®Google Scholar
• ZenewiczLAYancopoulosGDValenzuelaDMMurphyAJStevensSFlavellRAInnate and adaptive interleukin-22 protects mice from inflammatory bowel diseaseImmunity200819947957
   Web of Science ®Google Scholar
• VillanovaFFlutterBTosiICharacterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasisJ Invest Dermatol2014134498499124352038
   PubMed Web of Science ®Google Scholar
• TeunissenMBMunnekeJMBerninkJHComposition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patientsJ Invest Dermatol201413492351236024658504
   PubMed Web of Science ®Google Scholar
• SalimiMOggGInnate lymphoid cells and the skinBMC Dermatol2014141825427661
   PubMedGoogle Scholar
• FiorinoGOmodeiPDPsoriasis and inflammatory bowel disease: two sides of the same coin?J Crohns Colitis20159969769826079725
   PubMed Web of Science ®Google Scholar
• OuyangWKollsJKZhengYThe biological functions of T helper 17 cell effector cytokines in inflammationImmunity200828445446718400188
   PubMed Web of Science ®Google Scholar
• SteinmanLA brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damageNat Med200713213914517290272
   PubMed Web of Science ®Google Scholar
• ZenewiczLAAntovAFlavellRACD4 T-cell differentiation and inflammatory bowel diseaseTrends Mol Med200915519920719362058
   PubMed Web of Science ®Google Scholar
• ThompsonILeesCWGenetics of ulcerative colitisInflamm Bowel Dis201117383184821319274
   PubMed Web of Science ®Google Scholar
• GalvezJRole of Th17 cells in the pathogenesis of human IBDISRN Inflamm201425928461
   Google Scholar
• MarinoniBCeribelliAMassarottiMSelmiCThe Th17 axis in psoriatic disease: pathogenetic and therapeutic implicationsAuto Immun Highlights20145191926000152
   PubMedGoogle Scholar
• FitchEHarperESkorchevaIKurtzSEBlauveltAPathophysiology of psoriasis: recent advances on IL-23 and TH17 cytokinesCurr Rheumatol Rep20079646146718177599
   PubMedGoogle Scholar
• AsarchABarakOLooDSGottliebABTh17 cells: a new paradigm for cutaneous inflammationJ Dermatolog Treat200819525926618629676
   PubMed Web of Science ®Google Scholar
• HardenJLKruegerJGBowcockAMThe immunogenetics of psoriasis: a comprehensive reviewJ Autoimmun201564667326215033
   PubMed Web of Science ®Google Scholar
• SakaguchiSWingKMiyaraMRegulatory T cells – a brief history and perspectiveEur J Immunol200737Suppl 1S116S12317972355
   PubMed Web of Science ®Google Scholar
• SarutaMYuQTFleshnerPRCharacterization of FOXP3+CD4+ regulatory T cells in Crohn’s diseaseClin Immunol2007125328129017897887
   PubMed Web of Science ®Google Scholar
• YuQTSarutaMAvanesyanAFleshnerPRBanhamAHPapadakisKAExpression and functional characterization of FOXP3+CD4+ regulatory T cells in ulcerative colitisInflamm Bowel Dis200713219119917206665
   PubMed Web of Science ®Google Scholar
• MaulJLoddenkemperCMundtPPeripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel diseaseGastroenterology200512871868187815940622
   PubMed Web of Science ®Google Scholar
• WangYLiuXPZhaoZBExpression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel diseaseJ Dig Dis201112428629421791023
   PubMed Web of Science ®Google Scholar
• HiraharaKLiuLClarkRAYamanakaKFuhlbriggeRCKupperTSThe majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptorsJ Immunol200617774488449416982885
   PubMed Web of Science ®Google Scholar
• BovenschenHJvan Vlijmen-WillemsIMvan de KerkhofPCvan ErpPEIdentification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in PsoriasisDermatology2006213211111716902287
   PubMed Web of Science ®Google Scholar
• GaoLLiKLiFPolymorphisms in the FOXP3 gene in Han Chinese psoriasis patientsJ Dermatol Sci2010571515619880293
   PubMed Web of Science ®Google Scholar
• ParkOGrishinaILeungPSGershwinMEPrindivilleTAnalysis of the Foxp3/scurfin gene in Crohn’s diseaseAnn N Y Acad Sci2005105121822816126962
   PubMed Web of Science ®Google Scholar
• BinusAMHanJQamarAAModyEAHoltEWQureshiAAAssociated comorbidities in psoriasis and inflammatory bowel diseaseJ Eur Acad Dermatol Venereol201226564465021689167
   PubMed Web of Science ®Google Scholar
• AbuabaraKAzfarRSShinDBNeimannALTroxelABGelfandJMCause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UKBr J Dermatol201016358659220633008
   PubMed Web of Science ®Google Scholar
• OnumahNKircikLHPsoriasis and its comorbiditiesJ Drugs Dermatol2012115 SupplS5S10
   Web of Science ®Google Scholar
• CasellaGTontiniGEBassottiGNeurological disorders and inflammatory bowel diseasesWorld J Gastroenterol201420278764878225083051
   PubMed Web of Science ®Google Scholar
• CardTHubbardRLoganRFMortality in inflammatory bowel disease: a population-based cohort studyGastroenterology200312561583159014724808
   PubMed Web of Science ®Google Scholar
• Müller-HermelinkNBraumüllerHPichlerBTNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesisCancer Cell200813650751818538734
   PubMed Web of Science ®Google Scholar
• MantovaniAAllavenaPSicaABalkwillFCancer-related inflammationNature200845443644418650914
   PubMed Web of Science ®Google Scholar
• ZumstegAChristoforiGCorrupt policemen: inflammatory cells promote tumor angiogenesisCurr Opin Oncol200921607019125020
   PubMed Web of Science ®Google Scholar
• ZamarronBFChenWDual roles of immune cells and their factors in cancer development and progressionInt J Biol Sci2011765165821647333
   PubMed Web of Science ®Google Scholar
• BassukasIDGaitanisGTsianosEAzathioprine: an explanation for the risk of skin SCC among patients with Crohn’s disease?Ann Rheum Dis200968 eLetter June 15, 2009; Available from: http://ard.bmj.com/content/68/12/1863.full/reply#annrheumdis_el_5801Accessed May 3, 2016
   Google Scholar
• MonteiroRAzevedoIChronic inflammation in obesity and the metabolic syndromeMediators Inflamm2010201028964520706689
   PubMed Web of Science ®Google Scholar
• HammingaEAvan der LelyAJNeumannHAThioHBChronic inflammation in psoriasis and obesity: implications for therapyMed Hypotheses200667476877316781085
   PubMed Web of Science ®Google Scholar
• ArmstrongAWHarskampCTArmstrongEJThe association between psoriasis and obesity: a systematic review and meta-analysis of observational studiesNutr Diabetes20122e5423208415
   PubMed Web of Science ®Google Scholar
• MattioliBStrafaceEQuarantaMGGiordaniLVioraMLeptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 primingJ Immunol2005174116820682815905523
   PubMed Web of Science ®Google Scholar
• WangYChenJZhaoYGengLSongFChenHDPsoriasis is associated with increased levels of serum leptinBr J Dermatol200815851134113518294316
   PubMed Web of Science ®Google Scholar
• LomerMCCookWBJan-MohamedHJIron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel diseaseBr J Nutr20121071218061122152498
   PubMed Web of Science ®Google Scholar
• SteedHWalshSReynoldsNA brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, ScotlandObes Facts20092637037220090388
   PubMed Web of Science ®Google Scholar
• AndradeMMaioRDouradoKFMacêdoPFBarreto NetoACExcessive weight muscle – depletion paradox and cardiovascular risk factors in outpatients with inflammatory bowel diseaseArg Gastroenterol20155213745
   Google Scholar
• BertinBDesreumauxPDubuquoyLObesity, visceral fat and Crohn’s diseaseCurr Opin Clin Nutr Metab Care201013557458020625283
   PubMed Web of Science ®Google Scholar
• Chapman-KiddellCADaviesPSGillenLRadford-SmithGLRole of diet in the development of inflammatory bowel diseaseInflamm Bowel Dis201016113715119462428
   PubMed Web of Science ®Google Scholar
• MehtaNNYuYPinnelasRAttributable risk estimate of severe psoriasis on major cardiovascular eventsAm J Med20111248775.e1e621787906
   PubMed Web of Science ®Google Scholar
• BaltaIBaltaSDemirkolSAortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgarisAngiology2014651747823636854
   PubMed Web of Science ®Google Scholar
• NofalAAl-MakhzangyIAttwaENassarAAbdalmoatiAVascular endothelial growth factor in psoriasis: an indicator of disease severity and controlJ Eur Acad Dermatol Venereol200923780380619309427
   PubMed Web of Science ®Google Scholar
• McDonaldIConnollyMTobinAMA review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolismJ Nutr Metab2012201296538522690330
   PubMedGoogle Scholar
• DornSDSandlerRSInflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysisAm J Gastroenterol2007102366266717156143
   PubMed Web of Science ®Google Scholar
• GraefVBaggenstossAHSauerWGSpittellJAJrVenous thrombosis occurring in nonspecific ulcerative colitis. A necropsy studyArch Intern Med1966117377382
   Google Scholar
• RuisiPMakaryusJNRuisiMMakaryusANInflammatory bowel disease as a risk factor for premature coronary artery diseaseJ Clin Med Res20157425726125699123
   PubMedGoogle Scholar
• GisondiPCotenaCTessariGGirolomoniGAnti-tumour necrosis factor-α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort studyJ Eur Acad Dermatol Venereol200822334134418005022
   PubMed Web of Science ®Google Scholar
• RhoYHChungCPOeserAInflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritisArthritis Rheum200961111580158519877084
   PubMed Web of Science ®Google Scholar
• DagliNPoyrazogluOKDagliAFIs inflammatory bowel disease a risk factor for early atherosclerosis?Angiology20106119820419398421
   PubMed Web of Science ®Google Scholar
• MitchellGFArterial stiffness and wave reflection: biomarkers of cardiovascular riskArtery Res20093566420161241
   PubMedGoogle Scholar
• MichaRImamuraFWyler von BallmoosMSystematic review and meta-analysis of methotrexate use and risk of cardiovascular diseaseAm J Cardiol201110891362137021855836
   PubMed Web of Science ®Google Scholar
• FameniniSSakoEYWuJJEffect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitorsAm J Clin Dermatol2014151455024281789
   PubMed Web of Science ®Google Scholar
• AbuabaraKLeeHKimballABThe effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort studyBr J Dermatol20111651066107321777216
   PubMed Web of Science ®Google Scholar
• SaracenoRSagginiAPietroleonardoLChimentiSInfliximab in the treatment of plaque type psoriasisClin Cosmet Investig Dermatol200922737
   PubMedGoogle Scholar
• AkobengAKZachosMTumor necrosis factor-α antibody for induction of remission in Crohn’s diseaseCochrane Database Syst Rev20041CD00357414974022
   PubMedGoogle Scholar
• FiorinoGAllezMMalesciADaneseSReview article: anti TNF-α induced psoriasis in patients with inflammatory bowel diseaseAliment Pharmacol Ther200929992192719210297
   PubMed Web of Science ®Google Scholar
• MocciaroFRennaSOrlandoACottoneMSevere cutaneous psoriasis after certolizumab pegol treatment: report of a caseAm J Gastroenterol20091042867286819888257
   PubMed Web of Science ®Google Scholar
• HarrisMDRichardsRFirst case report of adalimumab-induced psoriasis in Crohn’s diseaseAm J Gastroenterol200910479279319262532
   PubMed Web of Science ®Google Scholar
• VereaMMDel PozoJYebra-PimentelMTPortaAFonsecaEPsoriasiform eruption induced by infliximabAnn Pharmacother200438545714742794
   PubMed Web of Science ®Google Scholar
• TichyMHercogovaJManifestation of Crohn’s disease in a young woman during the course of treatment for severe form of chronic plaque psoriasis with etanerceptDermatol Ther201427421121424548537
   PubMed Web of Science ®Google Scholar
• HarrisonMJDixonWGWatsonKDRates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF-α therapy: results from the British Society for Rheumatology Biologics RegisterAnn Rheum Dis20096820921518385277
   PubMed Web of Science ®Google Scholar
• YiuZZGriffithsCEInterleukin 17-A inhibition in the treatment of psoriasisExpert Rev Clin Immunol20161211426561053
   PubMed Web of Science ®Google Scholar
• TarganSFeaganBVermeireSMo2083 a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn’s diseaseGastroenterology20121433e26
   PubMed Web of Science ®Google Scholar
• OgawaAAndohAArakiYBambaTFujiyamaYNeutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in miceClin Immunol2004110556214962796
   PubMed Web of Science ®Google Scholar
• YenDCheungJScheerensHIL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6J Clin Invest20061161310131616670770
   PubMed Web of Science ®Google Scholar
• MonsenUSorstadJHellersGJohanssonCExtracolonic diagnoses in ulcerative colitis: an epidemiological studyAm J Gastroenterol1990857117162353691
   PubMed Web of Science ®Google Scholar
• DasKMRelationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesisDig Dis Sci19994411139952216
   PubMed Web of Science ®Google Scholar
• VavrickaSRBrunLBallabeniPFrequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohortAm J Gastroenterol2011106111011920808297
   PubMed Web of Science ®Google Scholar
• AtreyaRZimmerMBartschBAntibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophagesGastroenterology201114162026203821875498
   PubMed Web of Science ®Google Scholar
• ColombelJFSendidBJouaultTPoulainDSecukinumab failure in Crohn’s disease: the yeast connection?Gut201362800801
   PubMed Web of Science ®Google Scholar
• Eligius HellströmAFärkkiläMKolhoKLInfliximab-induced skin manifestations in patients with inflammatory bowel diseaseScand J Gastroenterol201651556357126728295
   PubMed Web of Science ®Google Scholar
• DenadaiRTeixeiraFVSaad-HossneRManagement of psoriatic lesions associated with anti-TNF therapy in patients with IBDNat Rev Gastroenterol Hepatol201291274423147656
   PubMed Web of Science ®Google Scholar
• CullenGKroshinskyDCheifetzASKorzenikJRPsoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literatureAliment Pharmacol Ther20113411–121318132721957906
   PubMed Web of Science ®Google Scholar
• GudjonssonJEKarasonARunarsdottirEHDistinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients – an analysis of 1019 HLA-C- and HLAB-typed patientsJ Invest Dermatol2006126474074516439971
   PubMed Web of Science ®Google Scholar
• AndersonCAMasseyDCBarrettJCInvestigation of Crohn’s disease risk loci in ulcerative colitis further defines their molecular relationshipGastroenterology20091362523529.e319068216
   PubMed Web of Science ®Google Scholar
• CargillMSchrodiSJChangMA large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genesAm J Hum Genet200780227329017236132
   PubMed Web of Science ®Google Scholar
• SafranyESzaboMSzellMDifference of interleukin-23 receptor gene haplotype variants in ulcerative colitis compared to Crohn’s disease and psoriasisInflamm Res201362219520023093364
   PubMed Web of Science ®Google Scholar
• CaponFDi MeglioPSzaubJSequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasisHum Genet2007122220120617587057
   PubMed Web of Science ®Google Scholar
• WolfNQuarantaMPrescottNJPsoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn diseaseJ Med Genet200845211411617993580
   PubMed Web of Science ®Google Scholar
• CaponFBijlmakersMJWolfNIdentification of ZNF313/RNF114 as a novel psoriasis susceptibility geneHum Mol Genet200817131938194518364390
   PubMed Web of Science ®Google Scholar
• KugathasanSBaldassanoRNBradfieldJPLoci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel diseaseNature Genet2008401211121518758464
   PubMed Web of Science ®Google Scholar
• HüffmeierULascorzJBeckerTCharacterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1J Med Genet2009461173674419525279
   PubMed Web of Science ®Google Scholar
• RiouxJDSilverbergMSDalyMJGenomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility lociAm J Hum Genet20006661863187010777714
   PubMed Web of Science ®Google Scholar
• HampeJShawSHSaizRLinkage of inflammatory bowel disease to human chromosome 6pAm J Hum Genet19996561647165510577918
   PubMed Web of Science ®Google Scholar
• RiouxJDDalyMJSilverbergMSGenetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn diseaseNature Genet20012922322811586304
   PubMed Web of Science ®Google Scholar
• StalderJFTennstedtDDeleuranMFragility of epidermis and its consequence in dermatologyJ Eur Acad Dermatol Venereol201428Suppl 4118
   Web of Science ®Google Scholar
• CameronALKirbyBGriffithsCECirculating natural killer cells in psoriasisBr J Dermatol2003149116016412890211
   PubMed Web of Science ®Google Scholar
• HueberWSandsBELewitzkySSecukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trialGut201261121693170022595313
   PubMed Web of Science ®Google Scholar
• GladmanDDPsoriatic arthritisRheum Dis Clin North Am1998248298449891713
   PubMed Web of Science ®Google Scholar
• AtzeniFDefendentiCDittoMCRheumatic manifestations in inflammatory bowel diseaseAutoimmun Rev2014131202323774109
   PubMed Web of Science ®Google Scholar
• LemosLLde Oliveira CostaJAlmeidaAMTreatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safetyRheumatol Int201434101345136024728068
   PubMed Web of Science ®Google Scholar
• TrikudanathanGVenkateshPGNavaneethanUDiagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel diseaseDrugs201272182333234923181971
   PubMed Web of Science ®Google Scholar
• ThapaSHadidHSchairerJImamWJafriSMEffect of inflammatory bowel disease-related characteristics and treatment interventions on cardiovascular disease incidenceAm J Med Sci2015350317518026226548
   PubMed Web of Science ®Google Scholar
• HughJVan VoorheesASNijhawanRIFrom the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapiesJ Am Acad Dermatol201470116817724184141
   PubMed Web of Science ®Google Scholar
• BasavarajKHAshokNMRashmiRPraveenTKThe role of drugs in the induction and/or exacerbation of psoriasisInt J Dermatol201049121351136121091671
   PubMed Web of Science ®Google Scholar
• DubeauMFIacucciMBeckPLDrug-induced inflammatory bowel disease and IBD-like conditionsInflamm Bowel Dis201319244545622573536
   PubMed Web of Science ®Google Scholar
• MieleLValloneSCefaloCPrevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasisJ Hepatol200951477878619664838
   PubMed Web of Science ®Google Scholar
• WenkKSArringtonKCEhrlichAPsoriasis and non-alcoholic fatty liver diseaseJ Eur Acad Dermatol Venereol201125438339120840346
   PubMed Web of Science ®Google Scholar
• TsaitasCSemertzidouASinakosEUpdate on inflammatory bowel disease in patients with primary sclerosing cholangitisWorld J Hepatol20146417818724799986
   PubMedGoogle Scholar
• GisbertJPGonzález-LamaYMatéJThiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic reviewAm J Gastroenterol20071021518152717391318
   PubMed Web of Science ®Google Scholar
• BangemannKSchulzWWohllebenJDepression and anxiety disorders among psoriasis patients: protective and exacerbating factorsHautarzt201465121056106125376619
   PubMed Web of Science ®Google Scholar
• WalkerJRGraffLADutzJPBernsteinCNPsychiatric disorders in patients with immune-mediated inflammatory diseases: prevalence, association with disease activity, and overall patient well-beingJ Rheumatol Suppl201188313522045976
   PubMedGoogle Scholar
• LereboursEGower-RousseauCMerleVStressful life events as a risk factor for inflammatory bowel disease onset: a population based case-control studyAm J Gastroenterol200710212213117100973
   PubMed Web of Science ®Google Scholar
• BernsteinCNBlanchardJFKliewerEWajdaACancer risk in patients with inflammatory bowel disease: a population-based studyCancer20019185486211241255
   PubMed Web of Science ®Google Scholar
• BeyaertRBeaugerieLVan AsscheGCancer risk in immune-mediated inflammatory diseases (IMID)Mol Cancer20131219823987103
   PubMed Web of Science ®Google Scholar
• PedersenNDuricovaDElkjaerMGamborgMMunkholmPJessTRisk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studiesAm J Gastroenterol20101051480148720332773
   PubMed Web of Science ®Google Scholar
• LaukoetterMGMennigenRHannigCMIntestinal cancer risk in Crohn’s disease: a meta-analysisJ Gastrointest Surg201115457658321152994
   PubMed Web of Science ®Google Scholar
• CanavanCAbramsKRMayberryJMeta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s diseaseAliment Pharmacol Ther2006231097111016611269
   PubMed Web of Science ®Google Scholar
• DignassAVan AsscheGLindsayJOThe second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current managementJ Crohns Colitis201041286221122489
   PubMed Web of Science ®Google Scholar
• AkihoHYokoyamaAAbeSPromising biological therapies for ulcerative colitis: A review of the literatureWorld J Gastrointest Pathophysiol20156421922726600980
   PubMedGoogle Scholar
• OlteanuRZotaAParadoxical reactions induced by tumor necrosis factor-α antagonists: a literature review based on 46 casesIndian J Dermatol Venereol Leprol201682171226728803
   PubMed Web of Science ®Google Scholar
• KivelevitchDMansouriBMenterALong term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritisBiologics2014816918224790410
   PubMedGoogle Scholar
• KaserANot all monoclonals are created equal – lessons from failed drug trials in Crohn’s diseaseBest Pract Res Clin Gastroenterol201428343744924913383
   PubMed Web of Science ®Google Scholar
• MozaffariSNikfarSAbdolghaffariAHAbdollahiMNew biologic therapeutics for ulcerative colitis and Crohn’s diseaseExpert Opin Biol Ther201414558360024502344
   PubMed Web of Science ®Google Scholar
• PuigLLópezAVilarrasaEGarcíaIEfficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time pointsJ Eur Acad Dermatol Venereol201428121633165324033851
   PubMed Web of Science ®Google Scholar
• WatanabeMHibiTMostafaNMLong-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn’s diseaseJ Crohns Colitis20148111407141624874893
   PubMed Web of Science ®Google Scholar
• ThorlundKDruytsEMillsEJFedorakRNMarshallJKAdalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysisJ Crohns Colitis20148757158124491514
   PubMed Web of Science ®Google Scholar
• CauliAPigaMLubranoEMarchesoniAFlorisAMathieuANew approaches in tumor necrosis factor antagonism for the treatment of psoriatic arthritis: certolizumab pegolJ Rheumatol Suppl201593707226523062
   PubMedGoogle Scholar
• MoonWPestanaLBeckerBEfficacy and safety of certolizumab pegol for Crohn’s disease in clinical practiceAliment Pharmacol Ther201542442844026081839
   PubMed Web of Science ®Google Scholar
• AroraZShenBBiological therapy for ulcerative colitisGastroenterol Rep201532103109
   Google Scholar
• CampanatiAGanzettiGGiuliodoriKMolinelliEOffidaniABiologic therapy in psoriasis: safety profileCurr Drug Saf201611141126463245
   PubMed Web of Science ®Google Scholar
• SimonEGGhoshSIacucciMMoranGWUstekinumab for the treatment of Crohn’s disease: can it find its niche?Therap Adv Gastroenterol2016912636
   PubMed Web of Science ®Google Scholar
• Cote-DaigneaultJBouinMLahaieRColombelJFPoitrasPBiologics in inflammatory bowel disease: what are the data?United European Gastroenterol J201535419428
   PubMed Web of Science ®Google Scholar
• JaleelTElmetsCWeinkleAKassiraSElewskiBSecukinumab (AIN-457) for the treatment of psoriasisExpert Rev Clin Pharmacol20169218720226647300
   PubMed Web of Science ®Google Scholar
• HueberWSandsBELewitzkySSecukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trialGut201261121693170022595313
   PubMed Web of Science ®Google Scholar
• GenentechVoluntary U.S. Market Withdrawal of Raptiva^® (Efalizumab)2009 Available from: www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM149681.pdfAccessed May 2, 2016
   Google Scholar
• MrowietzUDommSSystemic steroids in the treatment of psoriasis: what is fact, what is fiction?J Eur Acad Dermatol Venereol20132781022102522830601
   PubMed Web of Science ®Google Scholar
• NunesTBarreiro-de AcostaMMarin-JimenezINosPSansMOral locally active steroids in inflammatory bowel diseaseJ Crohns Colitis20137318319122784947
   PubMed Web of Science ®Google Scholar
• Czarnecka-OperaczMSadowska-PrzytockaAThe possibilities and principles of methotrexate treatment of psoriasis – the updated knowledgePostepy Dermatol Alergol201431639240025610355
   PubMed Web of Science ®Google Scholar
• VaysseTCarbonnelFMethotrexate in IBD: the return of the prodigal sonJ Crohns Colitis20159430330425814523
   PubMed Web of Science ®Google Scholar
• KanwarAJYadavSDograSPsoriasis: what is new in nonbiologic systemic therapy in the era of biologics?Indian J Dermatol Venereol Leprol201076662263321079305
   PubMed Web of Science ®Google Scholar
• AtwanAIngramJRAbbottROral fumaric acid esters for psoriasisCochrane Database Syst Rev20158CD010497
   Google Scholar
• CasiliGCordaroMImpellizzeriDDimethyl fumarate reduces inflammatory responses in experimental colitisJ Crohns Colitis201610447248326690241
   PubMed Web of Science ®Google Scholar
• SoleymaniTVassantachartJMWuJJComparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive reviewJ Drugs Dermatol201615329330126954314
   PubMed Web of Science ®Google Scholar
• ThinLWMurrayKLawranceICOral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic eraInflamm Bowel Dis20131971490149823615528
   PubMed Web of Science ®Google Scholar
• YamammotoTShimoyamaTUmegaeSMatsumotoKTacrolimus vs antitumor necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational studyAliment Pharmacol Ther201643670571626762838
   PubMed Web of Science ®Google Scholar
• HoentjenFSakurabaAHanauerSUpdate on the management of ulcerative colitisCurr Gastroenterol Rep201113547548521789495
   PubMedGoogle Scholar
• BhartiRMesalazine in treatment of psoriasisIndian J Dermatol Venereol Leprol199662423123220948062
   PubMedGoogle Scholar
• MojaLDaneseSFiorinoGDel GiovaneCBonovasSSystematic review with network meta-analysis: comparative efficacy and safety of budesnide and mesalazine for Crohns diseaseAliment Pahrmacol Ther2015411110551065
   Web of Science ®Google Scholar
• FeaganBGMacdonaldJKOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisCochrane Database Syst Rev201210CD00054423076890
   PubMed Web of Science ®Google Scholar
• Du VivierAMunroDDVerbovJTreatment of psoriasis with aza-thioprineBr Med J1974149514812392
   PubMed Web of Science ®Google Scholar
• ChandeNPattonPHTsoulisDJThomasBSMacDonaldJKAza-thioprine or 6-mercaptopurine for maintenance of remission in Crohn’s diseaseCochrane Database Syst Rev201510CD000067
   Google Scholar
• SoodRAnsariSClarkTHamlinPJFordACLong-term efficacy and safety of azathioprine in ulcerative colitisJ Crohns Colitis20159219119725518053
   PubMed Web of Science ®Google Scholar
• FalaLOtezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasisAm Health Drug Benefits20158Spec Feature10511026629274
   PubMedGoogle Scholar
• GordonJNProtheroJDThorntonCACC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel diseaseJ Crohns Colitis20093317518221172267
   PubMed Web of Science ®Google Scholar